Novartis UK HCP Portal
Published on Novartis UK HCP Portal (https://www.health.novartis.co.uk)

Home > Printer-friendly > Efficacy

Efficacy [1]

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Efficacy of LUCENTIS in different ophthalmic indications.

Indications1

LUCENTIS 0.5 mg is indicated in adults for:

  • The treatment of neovascular (wet) age-related macular degeneration (AMD)
  • The treatment of visual impairment due to diabetic macular oedema (DMO)
  • The treatment of proliferative diabetic retinopathy (PDR)
  • The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)
  • The treatment of visual impairment due to choroidal neovascularisation (CNV).

LUCENTIS 0.2 mg is indicated in preterm infants for:

  • The treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 3+) or AP-ROP (aggressive posterior ROP) disease.

 

AMD, age-related macular degeneration; DMO, diabetic macular oedema; ROP, retinopathy of prematurity.

Reference

  1. LUCENTIS® (ranibizumab) Summary of Product Characteristics, July 2020.
Rate this content: 
No votes yet

Source URL:https://www.health.novartis.co.uk/medicines/ophthalmology/lucentis/efficacy

Links
[1] https://www.health.novartis.co.uk/medicines/ophthalmology/lucentis/efficacy